DFO
CRNX icon

Duquesne Family Office’s Crinetics Pharmaceuticals CRNX Stock Holding History

Duquesne Family Office’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-122,700
Closed -$6.27M – 59
2024
Q4 		$6.27M Sell
122,700
-186,300
-60% -$10.4M 0.17% 65
2024
Q3 		$15.8M Hold
309,000
– – 0.53% 36
2024
Q2 		$13.8M Hold
309,000
– – 0.47% 37
2024
Q1 		$14.5M Buy
+309,000
New +$12.1M 0.33% 41

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Duquesne Family Office's CRNX Position: Q1 2025 in Review

Duquesne Family Office sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 122,700 shares — an estimated $6.27M sold.

Duquesne Family Office first reported a position in CRNX in Q1 2024 and held it in 4 quarters. The position peaked at $15.8M in Q3 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Duquesne Family Office reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Duquesne Family Office sold 122,700 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $6.27M.
  • Duquesne Family Office first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Duquesne Family Office's Crinetics Pharmaceuticals position peaked at $15.8M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Duquesne Family Office's 13F filing for Q1 2025, filed 15 May 2025.